Immatics (NASDAQ:IMTX) Sets New 52-Week Low – What’s Next?

Immatics N.V. (NASDAQ:IMTX – Get Free Report) reached a new 52-week low during mid-day trading on Thursday. The company traded as low as $5.87 and last traded at $5.9750, with a volume of 551,533 shares changing hands. The stock had previously closed at $6.10.

Analysts Set New Price Targets

IMTX has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Immatics in a research report on Friday, September 18th. Jefferies Financial Group restated a “buy” rating on shares of Immatics in a research note on Tuesday. Wall Street Zen cut shares of Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. Stifel Nicolaus began coverage on shares of Immatics in a research note on Tuesday, October 13th. They issued a “buy” rating and a $15.00 price target on the stock. Finally, Mizuho set a $21.00 price target on shares of Immatics in a report on Thursday, October 29th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Immatics currently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Get Our Latest Stock Analysis on IMTX

Immatics Price Performance

The stock has a 50-day moving average of $7.52 and a 200 day moving average of $9.36. The company has a market cap of $812.90 million, a P/E ratio of -3.07 and a beta of 1.38.

Immatics (NASDAQ:IMTX – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.07). The company had revenue of $7.84 million for the quarter, compared to the consensus estimate of $12.18 million. Immatics had a negative net margin of 533.26% and a negative return on equity of 52.54%. Sell-side analysts predict that Immatics N.V. will post -2.03 EPS for the current year.

Insider Activity at Immatics

In other news, Director Perceptive Advisors Llc purchased 863,060 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were acquired at an average cost of $8.69 per share, for a total transaction of $7,499,991.40. Following the completion of the acquisition, the director owned 11,246,516 shares in the company, valued at $97,732,224.04. This trade represents a 8.31% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 3.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Immatics

A number of hedge funds and other institutional investors have recently modified their holdings of IMTX. Goldman Sachs Group Inc. grew its holdings in shares of Immatics by 3.6% in the third quarter. Goldman Sachs Group Inc. now owns 398,004 shares of the company’s stock valued at $3,494,000 after acquiring an additional 13,833 shares in the last quarter. Integral Health Asset Management LLC purchased a new stake in shares of Immatics during the third quarter valued at approximately $6,058,000. Marshall Wace LLP bought a new stake in Immatics during the third quarter worth $3,685,000. Aberdeen Group plc lifted its holdings in Immatics by 89.0% during the third quarter. Aberdeen Group plc now owns 1,235,460 shares of the company’s stock worth $10,847,000 after acquiring an additional 581,856 shares during the period. Finally, Alps Advisors Inc. raised its stake in shares of Immatics by 46.2% during the 3rd quarter. Alps Advisors Inc. now owns 198,239 shares of the company’s stock worth $1,741,000 after purchasing an additional 62,640 shares during the period. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Company Profile

(Get Free Report)

Immatics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Founded in Germany in 2000, the company uses its target-discovery and development platforms to identify cancer-associated targets and create therapies designed to direct the immune system against tumor cells. Its pipeline includes engineered T-cell receptor (TCR) T-cell therapies, which modify a patient’s T cells to recognize specific tumor targets, as well as TCR bispecific therapies designed to connect T cells with cancer cells.

Featured Articles

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.